S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Avoid the upcoming bloodbath (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Avoid the upcoming bloodbath (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Avoid the upcoming bloodbath (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
S&P 500   4,179.83
DOW   32,908.27
QQQ   347.99
Stock market today: Global shares mostly rise after House approves debt ceiling deal
Avoid the upcoming bloodbath (Ad)
Alibaba Unveils Its Spin-Off Plans
The Most Upgraded Stocks From The Q1 Earnings Season
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
Oman launches $5B investment fund as part of efforts to diversify oil-dependant economy
Can the Dow's 2023 Runaway Winners Keep Running?
We Called (ARWR) In Advance, Which Stocks Are Next? (Ad)
KLA Shares Soars As Chip Equipment Makers Surge 21% In May
Can These Two Crypto Stocks Stage a Comeback?
NASDAQ:LGVN

Longeveron (LGVN) Stock Forecast, Price & News

$2.96
-0.05 (-1.66%)
(As of 05/31/2023 ET)
Compare
Today's Range
$2.95
▼
$3.09
50-Day Range
$2.52
▼
$4.00
52-Week Range
$2.50
▼
$8.79
Volume
7,627 shs
Average Volume
115,819 shs
Market Capitalization
$62.40 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
$12.50
ProfileAnalyst RatingsChartCompetitorsEarningsFinancialsInsider TradesInstitutional OwnershipHeadlinesSEC FilingsShort InterestSocial Media

Longeveron MarketRank™ Forecast

Analyst Rating
Buy
3.00 Rating Score
Upside/​Downside
322.3% Upside
$12.50 Price Target
Short Interest
Bearish
8.09% of Float Sold Short
Dividend Strength
N/A
Sustainability
N/A
News Sentiment
0.30mentions of Longeveron in the last 14 days
Based on 2 Articles This Week
Insider Trading
N/A
Proj. Earnings Growth
Growing
From ($0.95) to ($0.75) Per Share

Overall MarketRank™

MarketRank is calculated as an average of available category scores, with extra weight given to analysis and valuation.

1.92 out of 5 stars

Medical Sector

650th out of 1,006 stocks

Pharmaceutical Preparations Industry

325th out of 492 stocks

See Top Rated MarketRank™ Stocks Here

LGVN stock logo

About Longeveron (NASDAQ:LGVN) Stock

Longeveron Inc., a clinical stage biotechnology company, develops cellular therapies for aging-related and life-threatening conditions. The company's lead investigational product is the LOMECEL-B, a cell-based therapy product that is derived from culture-expanded medicinal signaling cells that are sourced from bone marrow of young healthy adult donors. It is conducting Phase 1 and 2 clinical trials in various indications, such as aging frailty, alzheimer's disease, metabolic syndrome, acute respiratory distress syndrome, and hypoplastic left heart syndrome. The company was incorporated in 2014 and is based in Miami, Florida.

Receive LGVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

LGVN Stock News Headlines

May 31, 2023 | americanbankingnews.com
Longeveron (NASDAQ:LGVN) vs. Tonix Pharmaceuticals (NASDAQ:TNXP) Head-To-Head Comparison
May 18, 2023 | americanbankingnews.com
Short Interest in Longeveron Inc. (NASDAQ:LGVN) Declines By 6.4%
June 1, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 17, 2023 | msn.com
EF Hutton Reiterates Longeveron Inc - (LGVN) Buy Recommendation
May 12, 2023 | finance.yahoo.com
LGVN: Announces Results and Progress on a Devastating Disease
May 12, 2023 | finance.yahoo.com
Longeveron Inc. Provides Corporate Update and Reports First Quarter 2023 Financial Results
May 12, 2023 | investorplace.com
LGVN Stock Earnings: Longeveron Misses EPS, Revenue Estimates
May 12, 2023 | msn.com
Preview: Longeveron's Earnings
June 1, 2023 | Behind the Markets (Ad)
"Unknown laser company making HUGE profit from Russia-Ukraine War"
On February 24th, Russia invaded Ukraine. This caused major stock losses and soaring gas prices. But it also created a HUGE opportunity for savvy investors. There's an unknown laser company that's been profiting greatly from this war... ...and from another major conflict happening 3,000 miles away. Learn more here >>>
May 11, 2023 | americanbankingnews.com
Longeveron (LGVN) Set to Announce Earnings on Friday
May 10, 2023 | markets.businessinsider.com
Longeveron Rallies 20% In Morning Trade
May 10, 2023 | finance.yahoo.com
Longeveron Announces New Long-Term Survival Data from ELPIS I Trial of Lomecel-B™ for Hypoplastic Left Heart Syndrome
May 10, 2023 | msn.com
Longeveron stock up 15.5% premarket after positive results in trial of treatment for rare congenital heart defect in infants
May 10, 2023 | msn.com
Longeveron spikes on long-term survival data for heart disease candidate
May 10, 2023 | markets.businessinsider.com
Longeveron (LGVN) Gets a Buy from EF Hutton
May 9, 2023 | finance.yahoo.com
Longeveron's Lomecel-BTM Shows Encouraging Survival Data, Keeps Hypoplastic Left Heart Syndrome Pediatric Patients Heart Transplant-Free
May 9, 2023 | investorplace.com
Why Is Longeveron (LGVN) Stock Up 30% Today?
May 8, 2023 | finance.yahoo.com
Longeveron to Announce First Quarter 2023 Financial Results on May 12, 2023
April 19, 2023 | finance.yahoo.com
Longeveron Announces First Patient Dosed in Phase 2 Clinical Trial of Lomecel-B™ for Aging-Related Frailty in Japan
March 29, 2023 | americanbankingnews.com
EF Hutton Acquisition Co. I Reiterates "Buy" Rating for Longeveron (NASDAQ:LGVN)
March 14, 2023 | finance.yahoo.com
Longeveron (NASDAQ:LGVN shareholders incur further losses as stock declines 18% this week, taking one-year losses to 51%
March 13, 2023 | finance.yahoo.com
LGVN: Longeveron Continues Progress Toward Important Treatments
March 12, 2023 | insidermonkey.com
Longeveron Inc. (NASDAQ:LGVN) Q4 2022 Earnings Call Transcript
March 10, 2023 | finance.yahoo.com
Longeveron Inc. Provides Corporate Update and Reports Fourth Quarter and Full Year 2022 Financial Results
March 6, 2023 | finance.yahoo.com
Longeveron to Announce Fourth Quarter and Full Year Financial Results on March 10, 2023
February 28, 2023 | finance.yahoo.com
Longeveron Appoints Wa’el Hashad as Chief Executive Officer
January 27, 2023 | finance.yahoo.com
Will Longeveron (NASDAQ:LGVN) Spend Its Cash Wisely?
See More Headlines
Receive LGVN Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Longeveron and its competitors with MarketBeat's FREE daily newsletter.

LGVN Company Calendar

Last Earnings
3/10/2023
Today
5/31/2023
Next Earnings (Estimated)
8/11/2023
Fiscal Year End
12/31/2023
Get Stock Alerts

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Industry
Pharmaceutical preparations
Sub-Industry
N/A
Sector
Medical
Current Symbol
NASDAQ:LGVN
CUSIP
N/A
CIK
1721484
Web
www.longeveron.com
Phone
305-302-7158
Fax
N/A
Employees
18
Year Founded
N/A

Price Target and Rating

Average Stock Price Forecast
$12.50
High Stock Price Forecast
$12.50
Low Stock Price Forecast
$12.50
Forecasted Upside/Downside
+322.3%
Consensus Rating
Buy
Rating Score (0-4)
3.00
Research Coverage
1 Analysts

Profitability

EPS (Most Recent Fiscal Year)
($0.95)
Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
$-18,830,000.00
Net Margins
-1,765.78%
Pretax Margin
-1,765.87%
Return on Equity
-87.96%
Return on Assets
-69.43%

Debt

Debt-to-Equity Ratio
N/A
Current Ratio
4.14
Quick Ratio
4.14

Sales & Book Value

Annual Sales
$1.13 million
Price / Sales
55.17
Cash Flow
N/A
Price / Cash Flow
N/A
Book Value
$0.77 per share
Price / Book
3.84

Miscellaneous

Outstanding Shares
21,082,000
Free Float
12,318,000
Market Cap
$62.40 million
Optionable
Not Optionable
Beta
0.55

Key Executives

  • Dr. Joshua Michael Hare FACC (Age 59)
    M.D., Co-Founder, Chief Science Officer & Chairman
    Comp: $449.81k
  • Mr. James Clavijo CPAMr. James Clavijo CPA (Age 56)
    CFO & Treasurer
    Comp: $481.07k
  • Mr. Paul T. Lehr J.D.Mr. Paul T. Lehr J.D. (Age 54)
    International Exec. Director, Gen. Counsel & Sec.
    Comp: $465.25k
  • Dr. Kwan-Hong Min M.D. (Age 55)
    Ph.D., Chief Medical Officer & Interim CEO
  • Dr. Dan Gincel Ph.D. (Age 51)
    Sr. VP of Strategic Collaborations & Scientific Affairs

Key Competitors

View All Competitors

Insiders

View All Insider Transactions













LGVN Stock - Frequently Asked Questions

Should I buy or sell Longeveron stock right now?

1 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Longeveron in the last twelve months. There are currently 1 buy rating for the stock. The consensus among Wall Street analysts is that investors should "buy" LGVN shares.
View LGVN analyst ratings or view top-rated stocks.

What is Longeveron's stock price forecast for 2023?

1 brokers have issued twelve-month price objectives for Longeveron's shares. Their LGVN share price forecasts range from $12.50 to $12.50. On average, they anticipate the company's share price to reach $12.50 in the next year. This suggests a possible upside of 322.3% from the stock's current price.
View analysts price targets for LGVN or view top-rated stocks among Wall Street analysts.

How have LGVN shares performed in 2023?

Longeveron's stock was trading at $3.22 at the start of the year. Since then, LGVN shares have decreased by 8.1% and is now trading at $2.96.
View the best growth stocks for 2023 here.

Are investors shorting Longeveron?

Longeveron saw a increase in short interest in May. As of May 15th, there was short interest totaling 403,500 shares, an increase of 160.0% from the April 30th total of 155,200 shares. Based on an average daily trading volume, of 152,100 shares, the days-to-cover ratio is presently 2.7 days. Approximately 8.1% of the shares of the stock are sold short.
View Longeveron's Short Interest.

When is Longeveron's next earnings date?

The company is scheduled to release its next quarterly earnings announcement on Friday, August 11th 2023.
View our LGVN earnings forecast.

How were Longeveron's earnings last quarter?

Longeveron Inc. (NASDAQ:LGVN) issued its earnings results on Friday, March, 10th. The company reported ($0.21) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.11. The firm had revenue of $0.12 million for the quarter, compared to the consensus estimate of $0.40 million. Longeveron had a negative net margin of 1,765.78% and a negative trailing twelve-month return on equity of 87.96%.

When did Longeveron IPO?

(LGVN) raised $30 million in an IPO on Friday, February 12th 2021. The company issued 2,700,000 shares at a price of $10.00-$12.00 per share. Kingswood Capital Markets and Alexander Capital L.P. acted as the underwriters for the IPO.

What is Longeveron's stock symbol?

Longeveron trades on the NASDAQ under the ticker symbol "LGVN."

How do I buy shares of Longeveron?

Shares of LGVN stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
Compare Top Brokerages Here.

What is Longeveron's stock price today?

One share of LGVN stock can currently be purchased for approximately $2.96.

How much money does Longeveron make?

Longeveron (NASDAQ:LGVN) has a market capitalization of $62.40 million and generates $1.13 million in revenue each year. The company earns $-18,830,000.00 in net income (profit) each year or ($0.95) on an earnings per share basis.

How can I contact Longeveron?

Longeveron's mailing address is 1951 NW 7TH AVENUE SUITE 520, MIAMI FL, 33136. The official website for the company is www.longeveron.com. The company can be reached via phone at 305-302-7158 or via email at brendan.payne@sternir.com.

This page (NASDAQ:LGVN) was last updated on 6/1/2023 by MarketBeat.com Staff

My Account -